Resources Year All 2019 2018 2017 2016 2015 2014 2013 2012 2010 Go Search Paper The exportin-1 inhibitor selinexor exerts superior anti-tumor activity when combined with T cell checkpoint inhibitors External Link Read MorePresentation A Phase 1/2 Study of the Second Generation Selective Inhibitor of Nuclear Export (SINE) Compound, KPT-8602, in Patients with Relapsed Refractory Multiple Myeloma PDF (922.01 KB) Read MorePresentation Selinexor in Combination with Bortezomib and Dexamethasone (SVd) Demonstrates Significant Activity in Patients with Refractory MM: Results of Phase I STOMP Trial (MCRN02) PDF (1.89 MB) Read MorePresentation A Phase I Study of Selinexor in Combination with Daunorubicin and Cytarabine in Patients with Newly Diagnosed Poor-Risk Acute Myeloid Leukemia PDF (350.19 KB) Read MorePresentation Final Results of Phase 1 MMRC Trial of Selinexor, Carfilzomib, and Dexamethasone in Relapsed/Refractory Multiple Myeloma PDF (1.89 MB) Read MorePresentation Selinexor Shows Synergy in Combination with Pomalidomide and Low Dose Dexamethasone in Patients with Relapsed / Refractory Multiple Myeloma: Phase I STOMP Trial PDF (3.21 MB) Read MorePresentation Selinexor and Low Dose Dexamethasone (Sd) in Patients with Lenalidomide, Pomalidomide, Bortezomib, Carfilzomib & anti-CD38 mAb Refractory MM: STORM Study PDF (1.15 MB) Read MorePresentation SAIL: Phase II Results of Ara-c and Idarubicin in Combination with the Selective Inhibitor of Nuclear Export (SINE™) Compound Selinexor (KPT-330) in Patients with Relapsed or Refractory AML PDF (622.01 KB) Read MorePresentation A Phase 1 Clinical Trial of Selinexor in Combination with Decitabine in Patients with Newly Diagnosed and Relapsed or Refractory Acute Myeloid Leukemia PDF (144.43 KB) Read MorePresentation Combination of Selinexor with High-Dose Cytarabine and Mitoxantrone for Remission Induction in Acute Myeloid Leukemia is Feasible and Tolerable – A Phase I Study PDF (2.33 MB) Read More Previous 1 … 4 5 6 7 8 … 22 Next